No Data
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
Express News | Shuttle Pharmaceuticals Appoints Timothy J. Lorber As Chief Financial Officer; Part-Time Role Transitioning To Full-Time On September 10, 2024
Express News | Shuttle Pharmaceuticals: Michael Vander Hoek Will Be Transitioning Out of His Role as Chief Financial Officer
Express News | Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Press Release: Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
12 Health Care Stocks Moving In Tuesday's After-Market Session
No Data
for?
